Novo Nordisk Faces a Fork in the Road as Pipeline Progress Meets Profit Pressure
Novo Nordisk stock trades 50% below peak amid GLP-1 competition from Eli Lilly’s oral pill, regulatory wins, and…
Novo Nordisk’s Pipeline Delivers Two Wins as Stock Sinks to Oversold Territory
Novo Nordisk secures rare disease and pediatric diabetes milestones, but shares fall 21% YTD on GLP-1 competition and…
Novo Nordisk’s CagriSema Data Locked as Pipeline Hopes Wrestle With a 50% Stock Wipeout
Novo Nordisk locks Phase 3 data for CagriSema vs Lilly’s Tirzepatid in diabetes, with shares at half their…
Novo Nordisk’s Oral Wegovy Pill Leaves Eli Lilly in the Dust as Pipeline Battles Loom
Novo Nordisk shares jump 6.4% as oral Wegovy prescriptions dwarf Eli Lilly’s rival, while pivotal CagriSema trial data…
Novo Nordisk’s Price and Pipeline Gambit to Revive Investor Confidence
Novo Nordisk slashes Wegovy HD price 40% vs Zepbound, launches subscription model, and advances oral Wegovy amid stock…
Novo Nordisk’s Pipeline Successor Outperforms Flagship Weight-Loss Drug
New clinical data shows UBT251 leads to 9.8% weight loss vs. semaglutide’s 4.8%, as Novo Nordisk expands its…
Orsted ‘Surprise’ Credit Downgrade Caps Worst Week on Record
(Bloomberg) — Orsted A/S was downgraded to the lowest tier of investment grade by S&P Global Ratings on…
Novo Nordisk Faces Mounting Challenges on Pricing and Pipeline
Novo Nordisk slashes US prices for Ozempic, Wegovy, and Rybelsus to $675/month in 2027. Its new obesity drug,…
Novo Nordisk’s new weight loss treatment inferior to tirzepatide
Novo Nordisk’s latest weight loss treatment, CagriSema, did not meet the primary endpoint of showing non-inferiority compared to…
Orsted Plans to Reinstate Dividend Even After Profit Misses
(Bloomberg) — Orsted A/S plans to reinstate dividends and ramp up spending this year, even after a string…
Aqueos Corporation acquires DSV Kelly Ann
Aqueos Corporation has strengthened its long-term commitment to safe surface and saturation diving and deepwater construction with the…